Literature DB >> 28290501

Steroidal[17,16-d]pyrimidines derived from dehydroepiandrosterone: A convenient synthesis, antiproliferation activity, structure-activity relationships, and role of heterocyclic moiety.

Shaoyong Ke1, Liqiao Shi1, Zhigang Zhang1, Ziwen Yang1.   

Abstract

A series of steroidal[17,16-d]pyrimidines derived from dehydroepiandrosterone were designed and prepared by a convenient heterocyclization reaction. The in vitro anticancer activities for these obtained compounds were evaluated against human cancer cell lines (HepG2, Huh-7, and SGC-7901), which demonstrated that some of these heterocyclic pyrimidine derivatives exhibited significantly good cytotoxic activities against all tested cell lines compared with 5-fluorouracil (5-FU), especially, compound 3b exhibited high potential growth inhibitory activities against all tested cell lines with the IC50 values of 5.41 ± 1.34, 5.65 ± 1.02 and 10.64 ± 1.49 μM, respectively, which might be used as promising lead scaffold for discovery of novel anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28290501      PMCID: PMC5349525          DOI: 10.1038/srep44439

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


With the constant increase in cancer mortality, cancer has gradually become one of the most complicated diseases that threaten public health of humans1. Although many effective therapeutic methods have been approved for cancer control, chemotherapy still remains a mainstay options for cancer treatment23. However, the emergence of side effects and multidrug-resistance have encouraged us to discover and identify novel synthetic or naturally occurring small molecules with highly effective bioactivity or therapeutic use. Therefore, searching for and developing new chemical entities with special characteristics as effective anticancer molecules are an important endeavor in the field of medicinal chemistry. It is well known that pyrimidine core has wide occurrence in nature4, and which has also represent a typical class of heterocyclic scaffold in various compounds applied in the field of medicinal chemistry56789101112131415, agrochemicals161718192021222324, and materials2526272829. Up to now, many pyrimidines analogues have been demonstrated to exhibit wide pharmacological activities mainly including anticancer, antiviral, antibacterial, antimalarial, antituberculosis activities. In particular, some compounds containing pyrimidine unit have been developed as highly effective anticancer or antibacterial drugs (Fig. 1), which further confirm pyrimidine ring is an important pharmacophore in the discovery of novel active molecules. Meanwhile, natural steroids, particularly dehydroepiandrosterone (DHEA) attract extensive interest of researchers, and many steroidal compounds bearing DHEA moiety have also emerged as highly potential pharmaceutical molecules due to their inherent bioactivity303132. Very recently, a series of DHEA-dihydrazone derivatives have also been investigated by us3334, and the results indicated some of the prepared molecules could inhibit the growth of human tumor cell lines, which also identify that this natural steroidal scaffold might contribute to the potential cytotoxic activity.
Figure 1

Representative structures for several pyrimidine derivatives.

Due to the above description and our ongoing interest in the discovery of novel functional heterocycles, we wish to integrate the structural features of pyrimidines and DHEA scaffold to a core structure as shown in Fig. 2, and explore the potential antiproliferative effects for these novel molecules derived from natural steroids. So we focused on the convenient synthesis, biological evaluation, and structure-activity relatioships of heterocyclic steroidal analogues. Therefore, a series of steroidal[17,16-d]pyrimidines derivatives 3a-p were synthesized according to the method shown in Fig. 3, and their cytotoxic effects on tumor cell lines (HepG2, Huh-7, SGC-7901) were also investigated by MTT colorimetric method, and the possible structure-activity relationships have also been summarized and discussed. These findings can provide interesting information for discovery of potential chemotherapeutic agents.
Figure 2

Design strategy of steroidal[17,16-d]pyrimidines.

Figure 3

Synthesis of steroidal[17,16-d]pyrimidines derivatives.

Results and Discussion

Chemistry

In this study, a series of heterocyclic steroidal[17,16-d]pyrimidines were synthesized via a sequence convenient transformation. The synthetic route for the preparation of these steroidal[17,16-d]pyrimidines derivatives 3a-p is outlined in Fig. 3. As shown in Fig. 3, the easily available natural steroid DHEA 1 was used as raw materials, which could be readily transferred to various substituted benzylidene-dehydroepiandrosterone derivatives 2a-p by a simple condensation reaction with various aldehydes in the presence of base. Then the treatment of intermediate 2a-p with guanidine nitrate formed the steroidal[17,16-d]pyrimidines 3a-p under the condition of base catalysis. Especially, the products for all these two steps are easy to separate and column chromatography isn’t required. All the newly prepared steroidal[17,16-d]pyrimidines derivatives 3a-p and the intermediates 2a-p gave satisfactory analyses mainly including 1H NMR, 13C NMR and ESI-MS spectrum, and their chemical structures and basic physiochemical properties were summarized in the Supporting Information.

Spectroscopy studies

All structures of target molecules 3a-p were determined by their 1H NMR, 13C NMR and mass spectroscopy, and all these spectral data were in good agreement with their structures. For 1H NMR spectrum, all assignments of the signals are based on their chemical shifts and intensity patterns. As shown in the representative 1H NMR spectrum (Fig. 4), all 1H NMR spectra of compounds 3a-p revealed the distinctive signals of methine proton attached to hydroxyl group, which showed a multiplet or broad singlet at 3.20–3.57 ppm. The signal for protons of alkene bond in DHEA scaffold was resonated as a singlet or doublet between δ 5.19–5.38 ppm. The other set of signals that emerged in their 1H NMR spectrum in the range of 3.19–0.85 ppm were assigned to the protons of DHEA skeleton, and the signals at lower fields in the corresponding 1H NMR spectrum were attributed to the aromatic protons as indicated in the general structures in Fig. 3. The 13C NMR spectra of compounds 3a-p display obvious peaks in the alkyl region indicating the presence of the DHEA scaffold. Other peaks appearing at lower fields were assigned to the aromatic and heterocyclic moiety. The electron spray impact mass spectra (ESI-MS) for compounds 3a-p was measured on a Waters ACQUITY UPLC® H-CLASS PDA (Waters®) instrument, and the ion peak or adduct ions of the compounds were explored. According to the experimental results, the ESI-MS of compounds 3a-p exhibit the obvious molecular peak [M + H]+ with high abundance (100%) in the positive ion mode. In addition, all feature peaks present in the 1H NMR and 13C NMR spectra for target derivatives are described in Supporting Information.
Figure 4

Representative 1H NMR spectra for compound 3a.

Inhibitory effects on the proliferation of cancer cells for the synthesized compounds

All obtained steroidal[17,16-d]pyrimidines derivatives 3a-p and the steroidal intermediates 2a-p were screened for their potential in vitro cytotoxic activity against HepG2 (human hepatocellular liver carcinoma), Huh-7 (human heptoma), and SGC-7901 (human gastric cancer) cell lines by the standard MTT assay35 using 5-fluorouracil as a control. The preliminary screened results were depicted in Fig. 5 and Table 1, and the IC50 value represents the drug concentration required to inhibit cell growth by 50%.
Figure 5

Antitumor activities of compounds 2a-p and 3a-p at 40 μg/mL.

Table 1

Cytotoxic activity of the steroidal derivatives.

EntryCompd.No.Substrates (R)In vitro cytotoxicity IC50a (μM)
HepG2bHuh-7bSGC-7901b
12aPh31.74 ± 6.1129.24 ± 5.6631.66 ± 7.71
22b2-ClPh29.21 ± 2.7827.67 ± 3.7127.04 ± 4.58
32c4-ClPh>95>95>95
42d2-FPh35.24 ± 3.9629.60 ± 7.0030.04 ± 5.18
52e4-FPh>100>100>100
62f2-CF3Ph24.09 ± 4.9118.30 ± 2.1421.63 ± 3.31
72g4-CF3Ph>90>90>90
82h2,4-Cl2Ph33.50 ± 3.4427.17 ± 5.7225.06 ± 5.07
92i2-F-4-BrPh72.21 ± 9.4050.88 ± 9.6434.25 ± 6.10
102j4-CH3OPh>95>95>95
112k4-CH3SPh>90>90>90
122l3,4,5-(CH3O)3Ph16.68 ± 2.5515.93 ± 3.2818.85 ± 3.43
132m2-Py>100>100>100
142n3-Py>100>100>100
152o4-Py>100>100>100
162p3-PhOPh>85>85>85
173aPh17.94 ± 2.1912.98 ± 3.2520.49 ± 3.76
183b2-ClPh5.41 ± 1.345.65 ± 1.0210.64 ± 1.49
193c4-ClPh>85>85>85
203d2-FPh9.58 ± 3.6012.53 ± 2.0517.33 ± 2.61
213e4-FPh16.80 ± 2.9121.92 ± 1.9623.61 ± 3.05
223f2-CF3Ph11.18 ± 2.4613.87 ± 2.2614.88 ± 1.53
233g4-CF3Ph12.17 ± 3.917.43 ± 1.3911.11 ± 0.83
243h2,4-Cl2Ph15.34 ± 3.336.02 ± 0.2513.35 ± 3.52
253i2-F-4-BrPh14.77 ± 4.528.69 ± 1.2118.88 ± 3.36
263j4-CH3OPh19.60 ± 5.1720.57 ± 5.7525.71 ± 2.07
273k4-CH3SPh20.42 ± 2.8622.85 ± 6.4224.67 ± 4.49
283l3,4,5-(CH3O)3Ph6.59 ± 1.785.38 ± 1.8415.71 ± 2.34
293m2-Py84.48 ± 6.77>95>95
303n3-Py22.84 ± 5.0925.10 ± 6.8733.97 ± 6.44
313o4-Py29.86 ± 7.3035.34 ± 10.0960.77 ± 2.67
323p3-PhOPh32.33 ± 6.86>7540.63 ± 2.23
33DHEAc39.04 ± 10.26>100>95
345-FUd>100>95>100

aIC50 – Compound concentration required to inhibit tumor cell proliferation by 50%.

bAbbreviations: HepG2 – Human hepatocellular liver carcinoma cell line; Huh-7 – Human hepatoma cell line; SGC-7901 – Human gastric cancer cell line.

cDHEA – Dehydroepiandrosterone.

d5-Fluorouracil, used as a positive control.

Generally, as indicated in Fig. 5, most of the heterocyclic steroidal[17,16-d]pyrimidines derivatives 3a-p displayed good cytotoxic activities than the corresponding steroidal intermediates 2a-p. Notably, the compounds 3a, 3b, 3d, 3e, 3f, 3g, 3h, and 3l exhibited excellent inhibitory activities against all three cell lines with 70–82% growth inhibition at the concentration of 40 μg/mL compared to the positive control 5-fluorouracil (58.6–70.5%). From Fig. 5, we also can observe that the typical compounds 3a, 3b, 3d, 3e, 3f, 3g, 3h, and 3l also presented better inhibitory activities than the natural compound DHEA (57.9–69.4%), which indicated these heterocyclic steroidal[17,16-d]pyrimidines can be used as a potential lead compounds for designing of novel anticancer drugs. Meanwhile, the bioassay revealed many of these heterocyclic compounds mainly including 3a, 3b, 3d, 3e, 3f, 3g, 3h, and 3l had good cytotoxic activities compared to 5-fluorouracil (Fig. 5), so in order to explore the highly potential activities, the IC50 values for these compounds 3a-p were further investigated and compared to 2a-p, DHEA and 5-fluorouracil. The popential inhibitory activities expressed as IC50 values for all compounds are shown in Table 1, which also demonstrated that some of the designed steroidal[17,16-d]pyrimidines derivatives 3a-p exhibited obviously inhibitory activities than the control 5-fluorouracil. Among all the compounds indicated in Table 1, compounds 3a, 3b, 3d, 3e, 3f, 3g, 3h, 3i, 3j, 3k, and 3l showed promising cytotoxic activities (Entries 17, 18, and 20–28) against all three cell lines. Especially, we also can find that compounds 3b, 3g, 3h, 3i and 3l exhibited a certain selective inhibition (Entries 18, 23, 24, 25 and 28) against all three cancer cell lines than the reference 5-fluorouracil. In addition, compound 3b showed the highest inhibitory effect on HepG2, Huh-7 and SGC-7901 cell lines, with an IC50 values of 5.41 ± 1.34, 5.65 ± 1.02 and 10.64 ± 1.49 μM, respectively. Moreover, the dose-response relationship of cell growth inhibition for highly potential compounds 3b, 3d, 3g, 3l and 5-fluorouracil have been presented in Fig. 6, which indicated that these heterocyclic compounds obviously inhibited HepG2, Huh-7, and SGC-7901 cell proliferation in a concentration-dependent manner. Especially, it should be pointed out that compound 3b containing an ortho-chlorophenyl unit (Entry 18 in Table 1) exhibited the most promising growth inhibitory effects on all three cell lines with the IC50 values of 5.41 ± 1.34, 5.65 ± 1.02 and 10.64 ± 1.49 μM, respectively, which was significantly better than the control 5-fluorouracil and DHEA.
Figure 6

Dose-response analysis of cell growth inhibition activity for the potential compounds 3b, 3d, 3g, 3l and 5-FU (positive control) against HepG2 (A), Huh-7 (B), and SGC-7901 (C) cell lines.

Structure and activity relationships (SARs)

The structure evolution here was to modify DHEA scaffold with pyrimidine ring system (3a-p) and aromatic enones (2a-p), respectively (Fig. 7). According to the in vitro bioassay results shown in Fig. 5 and Table 1, the possible structure-activity profile for these prepared steroidal derivatives can be obtained.
Figure 7

General structure-activity profile for these steroidal derivatives.

As indicated in Fig. 7, the compounds bearing pyrimidine ring system are general present better inhibition activities than the compounds modified by aromatic enones, which proved the importantance of heterocyclic pyrimidines. In addition, for the compounds containing pyrimidine ring system, the compounds bearing 2-ClPh and 3,4,5-(MeO)3Ph group present the highest potential activities, however, when the substituents R are 2-Py, 3-Py, 4-Py, and 3-PhOPh, which indicate low efficacy. Also, within the series of pyridine derivatives, the compound 3m bearing pyridin-2-yl substituent obviously decrease the cytotoxic activity. On the other hand, for the compounds containing aromatic enone moiety, the results testified that compounds containing 3,4,5-(MeO)3Ph and 2-CF3Ph group exhibited higher activity than the compounds bearing other substituents. From Table 1, we also can find that, within the series of halgen derivatives, it is clear that the ortho-substituted compound is better than the para-substituted compound. In particular, the two compounds containing 3,4,5-(MeO)3Ph group (2l and 3l) all present good inhibitory activities in these two systems, which may be due to the steric size of trisubstituted phenyl group is favourable for the binding to receptor. Taking into account these findings, it can be speculated it would have been more interesting to test the ortho-hydroxy and 3,4,5-trihydroxy substituted derivative, and the special properties of hydroxyl group will be helpful to increase the activity. These preliminary structure-activity relationships were to identify the target steroidal[17,16-d]pyrimidines derivatives that could serve as potential lead antitumor molecules for drug discovery, and the further structural optimization based on these obtained SAR are well under way in our laboratory.

Conclusion

Sixteen steroidal[17,16-d]pyrimidines derived from dehydroepiandrosterone were designed and synthesized via a sequence transformation, and their in vitro inhibitory activities against cell proliferation were evaluated. From the present data it was found that some of these heterocyclic steroidal[17,16-d]pyrimidines displayed significantly good cytotoxic activities against HepG2, Huh-7 and SGC-7901 cell lines compared to the reference 5-fluorouracil, which might be used as promising lead compounds for discovery of novel antitumor molecules. Further structural optimization and possible mechanism on these steroidal[17,16-d]pyrimidines will be investigated in due courses.

Experimental

Synthesis of target compounds

The instrumentation, chemicals, synthetic procedures and characterization were provided in supplementary data.

Biological evaluation

The in vitro cytotoxic activities of these steroidal molecules 2a-p and 3a-p against several human cancer cell lines (HepG2, Huh-7, SGC-7901) were determined using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide] method35, and the general procedures were previously reported in literatures3637. All the experimental data were analyzed by SPSS software, and the 50% inhibitory concentrations (IC50) of each molecule for the different cell lines were also measured. All biological evaluation was performed in triplicate on three independent experiments, and measurement data were expressed as the mean ± S. D.

Additional Information

How to cite this article: Ke, S. et al. Steroidal[17,16-d]pyrimidines derived from dehydroepiandrosterone: A convenient synthesis, antiproliferation activity, structure-activity relationships, and role of heterocyclic moiety. Sci. Rep. 7, 44439; doi: 10.1038/srep44439 (2017). Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
  28 in total

1.  Heterocycle-functional gramine analogues: solvent- and catalyst-free synthesis and their inhibition activities against cell proliferation.

Authors:  Shaoyong Ke; Liqiao Shi; Xiufang Cao; Qingyu Yang; Ying Liang; Ziwen Yang
Journal:  Eur J Med Chem       Date:  2012-05-12       Impact factor: 6.514

2.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

Review 3.  Oxidative metabolism of dehydroepiandrosterone (DHEA) and biologically active oxygenated metabolites of DHEA and epiandrosterone (EpiA)--recent reports.

Authors:  Laïla El Kihel
Journal:  Steroids       Date:  2011-10-02       Impact factor: 2.668

4.  Novel approaches for the synthesis of a library of fluorescent chromenopyrimidine derivatives.

Authors:  Afsaneh Zonouzi; Fatemeh Hosseinzadeh; Nastaran Karimi; Roghieh Mirzazadeh; Seik Weng Ng
Journal:  ACS Comb Sci       Date:  2013-04-18       Impact factor: 3.784

5.  Synthesis and fluorescence properties of pyrimidine mono- and bisboron complexes.

Authors:  Yasuhiro Kubota; Yousuke Ozaki; Kazumasa Funabiki; Masaki Matsui
Journal:  J Org Chem       Date:  2013-07-05       Impact factor: 4.354

Review 6.  Recent advances in the chemistry and biology of pyridopyrimidines.

Authors:  F Buron; J Y Mérour; M Akssira; G Guillaumet; S Routier
Journal:  Eur J Med Chem       Date:  2015-03-14       Impact factor: 6.514

7.  Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

Authors:  David S Carter; Muzaffar Alam; Haiying Cai; Michael P Dillon; Anthony P D W Ford; Joel R Gever; Alam Jahangir; Clara Lin; Amy G Moore; Paul J Wagner; Yansheng Zhai
Journal:  Bioorg Med Chem Lett       Date:  2009-02-07       Impact factor: 2.823

8.  Discovery of novel isatin-dehydroepiandrosterone conjugates as potential anticancer agents.

Authors:  Shaoyong Ke; Liqiao Shi; Ziwen Yang
Journal:  Bioorg Med Chem Lett       Date:  2015-08-20       Impact factor: 2.823

9.  MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.

Authors:  Helge Gad; Tobias Koolmeister; Ann-Sofie Jemth; Saeed Eshtad; Sylvain A Jacques; Cecilia E Ström; Linda M Svensson; Niklas Schultz; Thomas Lundbäck; Berglind Osk Einarsdottir; Aljona Saleh; Camilla Göktürk; Pawel Baranczewski; Richard Svensson; Ronnie P-A Berntsson; Robert Gustafsson; Kia Strömberg; Kumar Sanjiv; Marie-Caroline Jacques-Cordonnier; Matthieu Desroses; Anna-Lena Gustavsson; Roger Olofsson; Fredrik Johansson; Evert J Homan; Olga Loseva; Lars Bräutigam; Lars Johansson; Andreas Höglund; Anna Hagenkort; Therese Pham; Mikael Altun; Fabienne Z Gaugaz; Svante Vikingsson; Bastiaan Evers; Martin Henriksson; Karl S A Vallin; Olov A Wallner; Lars G J Hammarström; Elisee Wiita; Ingrid Almlöf; Christina Kalderén; Hanna Axelsson; Tatjana Djureinovic; Jordi Carreras Puigvert; Maria Häggblad; Fredrik Jeppsson; Ulf Martens; Cecilia Lundin; Bo Lundgren; Ingrid Granelli; Annika Jenmalm Jensen; Per Artursson; Jonas A Nilsson; Pål Stenmark; Martin Scobie; Ulrika Warpman Berglund; Thomas Helleday
Journal:  Nature       Date:  2014-04-02       Impact factor: 49.962

10.  Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease.

Authors:  Tao Su; Tianhua Zhang; Shishun Xie; Jun Yan; Yinuo Wu; Xingshu Li; Ling Huang; Hai-Bin Luo
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

View more
  3 in total

1.  Retracted Article: The synthesis and biological activity of marine alkaloid derivatives and analogues.

Authors:  Shiyang Zhou; Gangliang Huang
Journal:  RSC Adv       Date:  2020-08-28       Impact factor: 4.036

2.  Steroidal Pyrimidines and Dihydrotriazines as Novel Classes of Anticancer Agents against Hormone-Dependent Breast Cancer Cells.

Authors:  Alexander M Scherbakov; Alexander V Komkov; Anna S Komendantova; Margarita A Yastrebova; Olga E Andreeva; Valerii Z Shirinian; Alakananda Hajra; Igor V Zavarzin; Yulia A Volkova
Journal:  Front Pharmacol       Date:  2018-01-10       Impact factor: 5.810

3.  Novel d-Annulated Pentacyclic Steroids: Regioselective Synthesis and Biological Evaluation in Breast Cancer Cells.

Authors:  Svetlana K Vorontsova; Anton V Yadykov; Alexander M Scherbakov; Mikhail E Minyaev; Igor V Zavarzin; Ekaterina I Mikhaevich; Yulia A Volkova; Valerii Z Shirinian
Journal:  Molecules       Date:  2020-07-31       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.